Rendement sur 1 an (CAGR)
47.51%
Eli Lilly CDR (CAD Hedged) Exchange (TO, CAD)
LLY.TO
41.12
+0.48 (+1.18%)
TO
Loading...
Rendement sur 3 ans (CAGR)
-
Rendement sur 5 ans (CAGR)
-
Rendement sur 10 ans (CAGR)
-
Analyse boursière d'Objective Corporation – État au sein de l'État
Lire plusCapitalisation boursière
0.00
Cours/chiffre d'affaires
-
Valeur d'entreprise
-
Cours/valeur comptable
-
Rendement du div
0.60%
Années de croissance
1
Croissance du div
-
Versement FCF
-
Trailing P/E
-
PEG
-
P/E prévisionnel
-
Croissance EPS
-
Informations sur les actions
Qu'est-ce qu'une bourse ? Fonctionnement, acteurs, exemples
Lire plusGraphique boursier
Loading...
Données du prix des actions
| Ouverture | 41.00 |
| Max journalier | 41.40 |
| Min journalier | 40.73 |
| Volume journalier | 25K |
| Niveau record | 45.88 |
| Estimation des analystes sur 1 an | - |
| Beta | - |
| EPS (TTM) | - |
| Dividende par action | 0.25 |
| Date ex-div | 14 Aug 2026 |
| Prochaine date de bénéfices | - |
Potentiel de baisse
Loading...
Données du potentiel de baisse
| LLY.TO | S&P500 | |
| Baisse de prix actuelle par rapport au niveau record | -10.37% | -2.08% |
| Baisse de prix actuelle la plus importante | -36.25% | -56.47% |
| Date de la baisse la plus importante | 8 Aug 2025 | 9 Mar 2009 |
| Baisse moyenne par rapport au record | -9.97% | -10.68% |
| Délai moyen pour nouveau record | 11 days | 12 days |
| Délai max pour nouveau record | 300 days | 1805 days |
Actualite
Eli Lilly’s updated fair value estimate has shifted from US$1,297.31 to US$1,325.39, adding a fresh data point to an already closely watched price target range. This move sits alongside analyst price ...
20 septembre 2026
The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer Inc. is able to charge higher drug prices abroad, according to newly released documents.
19 septembre 2026
Investing.com -- Artificial intelligence is moving beyond text generation into scientific research, creating investment opportunities across AI infrastructure, pharmaceuticals, nuclear fusion, industr...
19 septembre 2026
It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company.
18 septembre 2026
Readers weigh in on energy investments, retirees’ dilemma, a Social Security fix, lessons from 9/11, and the case for natural-gas company Equinor.
18 septembre 2026
Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely...
18 septembre 2026
Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gam...
18 septembre 2026
Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry ...
18 septembre 2026
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree
18 septembre 2026